145 related articles for article (PubMed ID: 19040203)
1. In vivo (1)H MRS of WSU-DLCL2 human non-Hodgkin's lymphoma xenografts: response to rituximab and rituximab plus CHOP.
Lee SC; Delikatny EJ; Poptani H; Pickup S; Glickson JD
NMR Biomed; 2009 Apr; 22(3):259-65. PubMed ID: 19040203
[TBL] [Abstract][Full Text] [Related]
2. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
Plosker GL; Figgitt DP
Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
[TBL] [Abstract][Full Text] [Related]
3. In vivo MRS markers of response to CHOP chemotherapy in the WSU-DLCL2 human diffuse large B-cell lymphoma xenograft.
Lee SC; Huang MQ; Nelson DS; Pickup S; Wehrli S; Adegbola O; Poptani H; Delikatny EJ; Glickson JD
NMR Biomed; 2008 Aug; 21(7):723-33. PubMed ID: 18384181
[TBL] [Abstract][Full Text] [Related]
4. NMR metabolic and physiological markers of therapeutic response.
Lee SC; Poptani H; Delikatny EJ; Pickup S; Nelson DS; Schuster SJ; Nasta SD; Svoboda J; Goldstein SC; Wallace SG; Loevner LA; Mellon EA; Reddy R; Glickson JD
Adv Exp Med Biol; 2011; 701():129-35. PubMed ID: 21445779
[TBL] [Abstract][Full Text] [Related]
5. Early detection of radiation therapy response in non-Hodgkin's lymphoma xenografts by in vivo 1H magnetic resonance spectroscopy and imaging.
Lee SC; Poptani H; Pickup S; Jenkins WT; Kim S; Koch CJ; Delikatny EJ; Glickson JD
NMR Biomed; 2010 Jul; 23(6):624-32. PubMed ID: 20661875
[TBL] [Abstract][Full Text] [Related]
6. Effective immunochemotherapy for aggressive non-Hodgkin's lymphoma.
Coiffier B
Semin Oncol; 2004 Feb; 31(1 Suppl 2):7-11. PubMed ID: 15042528
[TBL] [Abstract][Full Text] [Related]
7. Rituximab-CHOP-ESHAP vs CHOP-ESHAP-high-dose therapy vs conventional CHOP chemotherapy in high-intermediate and high-risk aggressive non-Hodgkin's lymphoma.
Intragumtornchai T; Bunworasate U; Nakorn TN; Rojnuckarin P
Leuk Lymphoma; 2006 Jul; 47(7):1306-14. PubMed ID: 16923561
[TBL] [Abstract][Full Text] [Related]
8. Phase II study of rituximab in combination with chop chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma.
Vose JM; Link BK; Grossbard ML; Czuczman M; Grillo-Lopez A; Gilman P; Lowe A; Kunkel LA; Fisher RI
J Clin Oncol; 2001 Jan; 19(2):389-97. PubMed ID: 11208830
[TBL] [Abstract][Full Text] [Related]
9. In vivo monitoring response to chemotherapy of human diffuse large B-cell lymphoma xenografts in SCID mice by 1H and 31P MRS.
Huang MQ; Nelson DS; Pickup S; Qiao H; Delikatny EJ; Poptani H; Glickson JD
Acad Radiol; 2007 Dec; 14(12):1531-9. PubMed ID: 18035282
[TBL] [Abstract][Full Text] [Related]
10. Superior antitumor activity of SAR3419 to rituximab in xenograft models for non-Hodgkin's lymphoma.
Al-Katib AM; Aboukameel A; Mohammad R; Bissery MC; Zuany-Amorim C
Clin Cancer Res; 2009 Jun; 15(12):4038-45. PubMed ID: 19509168
[TBL] [Abstract][Full Text] [Related]
11. Genistein sensitizes diffuse large cell lymphoma to CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) chemotherapy.
Mohammad RM; Al-Katib A; Aboukameel A; Doerge DR; Sarkar F; Kucuk O
Mol Cancer Ther; 2003 Dec; 2(12):1361-8. PubMed ID: 14707277
[TBL] [Abstract][Full Text] [Related]
12. Aurora A inhibitor (MLN8237) plus vincristine plus rituximab is synthetic lethal and a potential curative therapy in aggressive B-cell non-Hodgkin lymphoma.
Mahadevan D; Stejskal A; Cooke LS; Manziello A; Morales C; Persky DO; Fisher RI; Miller TP; Qi W
Clin Cancer Res; 2012 Apr; 18(8):2210-9. PubMed ID: 22374334
[TBL] [Abstract][Full Text] [Related]
13. First-line treatment with brief-duration chemotherapy plus rituximab in elderly patients with intermediate-grade non-Hodgkin's lymphoma: phase II trial.
Hainsworth JD; Litchy S; Lamb MR; Rodriguez GI; Scroggin C; Greco FA
Clin Lymphoma; 2003 Jun; 4(1):36-42. PubMed ID: 12837153
[TBL] [Abstract][Full Text] [Related]
14. Monoclonal antibodies in the treatment of non-Hodgkin's lymphoma.
Fanale MA; Younes A
Drugs; 2007; 67(3):333-50. PubMed ID: 17335294
[TBL] [Abstract][Full Text] [Related]
15. Early response assessment using 3'-deoxy-3'-[18F]fluorothymidine-positron emission tomography in high-grade non-Hodgkin's lymphoma.
Herrmann K; Wieder HA; Buck AK; Schöffel M; Krause BJ; Fend F; Schuster T; Meyer zum Büschenfelde C; Wester HJ; Duyster J; Peschel C; Schwaiger M; Dechow T
Clin Cancer Res; 2007 Jun; 13(12):3552-8. PubMed ID: 17575218
[TBL] [Abstract][Full Text] [Related]
16. The addition of bryostatin 1 to cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy improves response in a CHOP-resistant human diffuse large cell lymphoma xenograft model.
Mohammad RM; Wall NR; Dutcher JA; Al-Katib AM
Clin Cancer Res; 2000 Dec; 6(12):4950-6. PubMed ID: 11156256
[TBL] [Abstract][Full Text] [Related]
17. Immunochemotherapy in indolent non-Hodgkin's lymphoma.
Czuczman MS
Semin Oncol; 2002 Apr; 29(2 Suppl 6):11-7. PubMed ID: 12040529
[TBL] [Abstract][Full Text] [Related]
18. Navitoclax (ABT-263) and bendamustine ± rituximab induce enhanced killing of non-Hodgkin's lymphoma tumours in vivo.
Ackler S; Mitten MJ; Chen J; Clarin J; Foster K; Jin S; Phillips DC; Schlessinger S; Wang B; Leverson JD; Boghaert ER
Br J Pharmacol; 2012 Oct; 167(4):881-91. PubMed ID: 22624727
[TBL] [Abstract][Full Text] [Related]
19. Use of rituximab in combination with conventional chemotherapy for the treatment of non-Hodgkin's lymphoma of the head and neck.
Manolopoulos L; Gomatos IP; Leandros E; Alevizos L; Georgiou N; Giotakis J; Ferekidis E
In Vivo; 2009; 23(3):475-8. PubMed ID: 19454517
[TBL] [Abstract][Full Text] [Related]
20. Incidence of interstitial pneumonitis in non-Hodgkin's lymphoma patients receiving immunochemotherapy with pegylated liposomal doxorubicin and rituximab.
Zhou T; Shen Q; Peng H; Chao T; Zhang L; Huang L; Yang K; Thapa S; Yu S; Jiang Y
Ann Hematol; 2018 Jan; 97(1):141-147. PubMed ID: 29086009
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]